Jonas Salk

Jonas Salk the American medical researcher and virologist (1914-1995) who developed the first effective vaccine against poliomyelitis, announced as safe and potent in 1955. Rather than patenting the vaccine, he chose to release it freely to the world, and his work is credited with the near-elimination of a disease that had paralysed tens of thousands of children each year.

Early Life and Training

Jonas Edward Salk was born on 28 October 1914 in New York City, the eldest son of Jewish immigrant parents of modest means. He grew up in the Bronx and attended the City College of New York, where he earned a bachelor's degree in 1934. He then entered the New York University School of Medicine, graduating in 1939, and decided early that he wished to devote himself to research rather than to clinical practice. He was the first member of his family to attend college, and his parents took great pride in his academic achievements.

After medical school Salk worked on influenza virus vaccines at the University of Michigan under Thomas Francis, a leading authority on immunology. There he helped to develop killed-virus vaccines that were given to the armed forces during the Second World War. This experience convinced him that a virus could be rendered harmless by chemical inactivation and yet still provoke protective immunity, an idea central to his later polio work. Francis remained a mentor and later directed the independent evaluation of the polio field trial that made Salk famous.

The Polio Problem and the Salk Vaccine

Poliomyelitis had become one of the most feared diseases of the postwar industrial world, striking in summer epidemics and leaving many children permanently paralysed. In 1947 Salk became director of the virus research laboratory at the University of Pittsburgh, and he set out to produce a vaccine from poliovirus grown in cultured monkey kidney cells and then killed with formalin. He faced two difficult problems: the virus had to be grown in quantity in living tissue, and it had to be inactivated fully enough to be safe, yet not so harshly that it lost its power to provoke immunity.

Salk's approach contradicted the prevailing belief, championed by many authorities, that only a live weakened virus could produce lasting immunity. He argued that a properly inactivated virus could stimulate the body to make antibodies without causing disease, and he tested the preparation extensively on himself, his family and volunteers. The vaccine was judged safe and effective after a massive national field trial in 1954 that involved nearly two million children. The trial, organised by the National Foundation for Infantile Paralysis, was one of the largest medical experiments ever conducted.

The 1955 Announcement and Public Response

On 12 April 1955 the results of the field trial were announced, and the vaccine was licensed for use the same day. The news was received as a national deliverance; church bells rang, and Salk became an instant hero. The following years saw a steep decline in polio cases in the United States and other countries where the vaccine was used. Parents who had once kept their children away from swimming pools and crowds now lined up to have them immunised.

A serious setback occurred when some batches produced by a particular manufacturer contained incompletely inactivated virus and caused cases of paralysis. The episode led to stricter manufacturing standards and strengthened public confidence once the regulations had been tightened. The surgeon general asked Salk to help devise the safeguards, and the episode became a lasting lesson in the importance of rigorous quality control in the production of biological medicines.

Choice Not to Patent, and the Salk Institute

When asked who owned the patent on the vaccine, Salk famously replied that there was no patent and that one could not patent the sun. He believed that the vaccine belonged to all people, and his decision not to seek personal profit from it enhanced his reputation for moral seriousness and was widely admired across the world. The choice was consistent with his view that medicine was a public trust rather than a private enterprise.

In 1963 Salk founded the Salk Institute for Biological Studies in La Jolla, California, a research centre intended to bring together the life sciences in a setting devoted to fundamental inquiry. He later worked on vaccines against other viruses and, in the final decades of his life, on an experimental vaccine against AIDS. He hoped the institute would foster the kind of patient, curiosity-driven research that had made his own vaccine possible, and he died on 23 June 1995, having dedicated his life to the prevention of disease.

Influence and Legacy

The Salk vaccine marked a turning point in the control of epidemic disease and helped to establish the principle that mass immunisation could reshape public health. It also stimulated the later development of the oral vaccine by Albert Sabin, whose live preparation proved easier to administer and eventually became the dominant tool in global eradication campaigns. Between the two vaccines, polio was eliminated from most of the world within a few decades.

Salk received the Presidential Medal of Freedom and many other distinctions, but he is remembered above all for a single act of applied science with incalculable human benefit. His career illustrates the power of a clear practical goal, combined with patient experimental work, to defeat a disease that had seemed unconquerable. He never won a Nobel Prize, a fact often remarked upon, yet his name remains inseparable from one of the great triumphs of preventive medicine.

See also

• Poliomyelitis
• Albert Sabin
• Killed-virus vaccine
• Salk Institute for Biological Studies